XML 58 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
AstraZeneca          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty $ 46   $ 46   $ 12
Payables to counterparty 892   892   643
AstraZeneca | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total sales 49 $ 5 125 $ 5  
AstraZeneca | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 12 0 48 0  
AstraZeneca | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 12 0 28 0  
AstraZeneca | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 47 2,377 118 2,377  
Eisai          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty 42   42    
Payables to counterparty 733   733    
Eisai | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total sales 43   78    
Eisai | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 8   9    
Eisai | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 5   7    
Eisai | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 36   1,473    
Bayer AG          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty 36   36   33
Payables to counterparty 375   375   $ 352
Bayer AG | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net product sales recorded by Merck 47 38 138 105  
Merck’s profit share from sales in Bayer’s marketing territories 47 32 100 116  
Total sales 94 70 238 221  
Bayer AG | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 29 25 188 73  
Bayer AG | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 11 6 26 18  
Bayer AG | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses $ 34 $ 27 $ 90 $ 78